
mRNAããŒã¹ãã¯ã¯ãã³ãæè¡ã«ãããããžã®éºäŒåå·¥åŠ
odysee Kla.TV - English 2024幎04æ27æ¥ããã
ãã€ã©ã€ãïŒ
mRNAã³ããã¯ã¯ãã³æ¥çš®ã¯ããã¯ãã¯ã¯ãã³æ¥çš®ãšã¯åŒã°ãããmodRNAããŒã¹ã®ã¯ã¯ãã³æè¡ãšåŒã°ããŠããã
modRNAã¯ãã现èã®DNAã«çµã¿èŸŒãŸããå¯èœæ§ãããã
mRNAã¯ã¯ãã³æè¡ã«é¢ããç§åŠçç ç©¶çµæã¯ãäžçäžã§å ¥æå¯èœã§ãããã€ã³ã¿ãŒãããã§ã¢ã¯ã»ã¹ã§ããã
mRNAããŒã¹ã®ã¯ã¯ãã³æè¡ã«é¢ããææ°ã®ç ç©¶ææãªãŒãã¬ãã(PDF)ïŒ
GAME OVER for the mRNA-based âvaccineâ technology
ããã¬ãŒã¿ãŒãmRNAãã¯ã¯ãã³ãæè¡ã§æ¥çš®ããã人ã ã¯ãéºäŒåçµæãçç©ãªã®ã§ããããïŒããªããã®ã¯ã¯ãã³ã¯æ¯ä¹³ã«ç§»è¡ããã®ã§ããããïŒããããŠããªããããã®ã¯ã¯ãã³ã®DNAæ±æããæ°ããã¿ã€ãã®çãã¿ãŒãçãåŒãèµ·ããå¯èœæ§ãããã®ã§ããããïŒ
ãã®çªçµã§ã¯ãmRNAã䜿ã£ããã¯ã¯ãã³ãæè¡ããªã人éã«ãšã£ãŠå±éºãªã®ããã玹ä»ããŸãã
ãã¢ããŠã³ãµãŒã2019幎ãã³ãããŠã€ã«ã¹ã®ãã³ãããã¯ã®éãæ°ããã¿ã€ãã®ã¯ã¯ãã³æè¡ã§ããmRNAã¯ã¯ãã³æè¡ãåããŠããã«äœ¿çšãããŸããã
åœæããå»åž«ãã¡ã¯ããã®æ°ãããã¯ãããžãŒã¯ããã®åœ±é¿ã«ã€ããŠæ¬æ Œçãªç§åŠçç ç©¶ãè¡ãããããšãªããå šäººé¡ã察象ãšããå®å°è©Šéšã§ãããšèŠåããŠããŸããã
ãã®ã¯ã¯ãã³æè¡ã®å°å ¥ãã4幎è¿ããçµéãã仿¥ãmRNAãçšããæè¡ãããããçµæã«ã€ããŠã®æžå¿µã¯ãæ®å¿µãªããå šãŠçŸå®ã®ãã®ãšãªããŸããã
ååçç©åŠè ã®ã¯ã©ãŠã¹ã»ã·ã¥ããŒã¬ãŒææãšãRNAãšãšããžã§ããã£ã¯ã¹ã®å°éå®¶ã§ããã¢ã¬ã¯ãµã³ãã©ã»ãã³ãªãªã³ïŒã¯ãŒãææã¯ãmRNAããŒã¹ã®ã¯ã¯ãã³æè¡ã«é¢ããææ°ã®ç ç©¶çµæããªãŒãã¬ããã«ãŸãšããŸããã
ã¿ã€ãã«ã¯ãGAME OVER for the mRNA-based âvaccineâ technology (mRNAããŒã¹ãã¯ã¯ãã³ãæè¡ãã²ãŒã ã¯çµã£ã)
ç°¡åã«ãŸãšããåã«ãçšèªã«ã€ããŠå°ã説æããŸããmRNAã³ããã¯ã¯ãã³æ¥çš®ã¯ããã¯ãã¯ã¯ãã³æ¥çš®ãšã¯åŒã°ãããããã«äœ¿çšãããmodRNAããŒã¹ã®ã¯ã¯ãã³æè¡ãšåŒã°ããŠããŸããmodRNAãšããã®ã¯ã人工çã«äœãããmRNAã§ãäœå ã®ããã®mRNAãšã¯æ¯èŒã§ããªãããã§ãã
çç©åŠè ã®ãŠã«ãªã±ã»ã±ã ã¡ã©ãŒææã«ããã°ãã³ãããŠã€ã«ã¹ã®ã¯ã¯ãã³æ¥çš®ã¯ã¯ã¯ãã³æ¥çš®ãšåŒãã§ã¯ãªããªããšã®ããšã§ããã±ã ã¡ã©ãŒå士ã¯ã€ã³ã¿ãã¥ãŒã®äžã§æ¬¡ã®ããã«è¿°ã¹ãŠããŸãã
ãã±ã ã¡ã©ãŒå士ã®èšèãããã®æå³ã§ã¯ã¯ã¯ãã³ã§ã¯ãªããéºäŒåå·¥åŠã§ããéºäŒåæ²»çã§ããããŸããããªããªãäœãæ²»çãããŠããããéºäŒåå·¥åŠãªã®ã§ãããã
ããã¯éºäŒåæäœã®å¿çšã§ãããäžæ¹ãå®éã®ã¯ã¯ãã³ã§ã¯ãæ»æ» ããç åäœãŸãã¯æ§é äœãããªãã¡ç åäœã®ã¿ã³ãã¯è³ªã泚å°ãããŸãããã®å Žåãäœå ã§å¢æ®ã§ããããæç¹ã§åè§£ãããéãæ±ºãŸã£ãŠããŸããèšã£ãŠã¿ãã°ãå ç«åå¿ã ããæ®ãã®ã§ãã
ãããä»ãæ°æè¡ã§ã¯ã人éã®çްèã«çºé µäžã®ãã¯ããªã¢ã®ãããªåãããããŸããã€ãŸããã¯ã¯ãã³ã®å®ç©ã现èã«è£œé ããããšããããšããããããããã©ã®çšåºŠå¹æçã«é²è¡ããã®ããã©ã®çšåºŠã®æéé²è¡ããã®ãããããäžçç¶ãã®ãã©ãããçŽ°èæ žã«å ¥ã蟌ãã®ãã©ãããããããªããŸãŸãè¡ãã®ã§ãã
ã€ãŸããå°æ¥ã®ã¯ã¯ãã³ãå«ããŠããããã®æ³šå°ãåãã人ã¯å šãŠãç¥ããç¥ããã®ãã¡ã«éºäŒåçµæãçç©ã«ãªããšããããšã§ãã
ãã¢ããŠã³ãµãŒãç ç©¶çµæã®èŠçŽã¯ä»¥äžã®éãã§ãã
ã¯ã¯ãã³ãšãã圢ã®mRNAæè¡ã¯ãããã«æ¬¡ã®ãããªçµæãããããå¯èœæ§ããããŸããäœå ã®ããããèåšã«ãããæ ¢æ§ççãäŸãã°å¿çãå¿èã®ççã
modRNAã¯ãã现èã®DNAã«çµã¿èŸŒãŸããå¯èœæ§ããããŸãããããç·æ§ãŸãã¯å¥³æ§ã®çæ®çްèã§èµ·ãããšã次äžä»£ã®ã²ãã ãæ¹å€ãããããšã«ãªããŸãã
modRNAã¯ã¯ãã³æè¡ã¯ãmodRNAãäœå ã®çްèã«çµã¿èŸŒãããšã§ãæ°ããã¿ã€ãã®çããæ¢ã«æ£ã£ãŠãã人ã®ã¿ãŒãçãåŒãèµ·ããå¯èœæ§ããããŸãã
以äžã§ã¯ãKla.TVããªãŒãã¬ããããããã€ãã®ç¹ãèŠçŽãããããçç¥ãã圢ã§ããã«ç޹ä»ããŸãããªãŒãã¬ããã®å šæã¯äžã®éãæ å ã«ãããŸãã
ããã¬ãŒã¿ãŒã1.ã圌ããèšãããšã¯ããããã¯ã¯ã¯ãã³ã§ããââãããéããŸãã
ãã¢ããŠã³ãµãŒãéºäŒåçµæã補åã®åºæºãå šãŠæºãããŠããããããã¯ã¯ãã³ãã§ã¯ãããŸãããããã¯åæçã«äœããã修食mRNAãmodRNAãå«ãã§ãããmodRNAã现èå ã«èŒžéããè質ããç²åã«å ãŸããŠããŸãã
ããã¬ãŒã¿ãŒã2. ãããã¯mRNAã§ãããšèšãããŸãããããã§ã¯ãããŸããã
ãã¢ããŠã³ãµãŒãããã¯mRNAã§ã¯ãªãã修食ãããmRNAãã€ãŸãmodRNAã§ãããã®åæãããmodRNAã¯å€©ç¶ã®mRNAãæš¡å£ããŠããŸãããå šãç°ãªãç¹åŸŽãæã£ãŠããŸãã
æ¥éã«åè§£ããã倩ç¶ã®mRNAãšã¯ç°ãªããCovid-19ãã¯ã¯ãã³ãã®modRNAã¯ãè¡æ¶²äžã§æé·28æ¥éãçµç¹äžã§æé·8é±éæ€åºãããŸããæ³šå ¥ãããmodRNAã«ãã£ãŠç£çãããã¹ãã€ã¯ã¿ã³ãã¯è³ªã¯ãæé·ã§6ã¶æéè¡æ¶²äžã埪ç°ããããšã確èªãããŠããŸãã
DNAãã¯ã¯ãã³ããæ€åºãããŸããããããã¯å šãäºæ³å€ã®ããšã§ããã¯ã¯ãã³ã®ããããã倧éã®DNAäžçŽç©ãèŠã€ãã£ãŠãããçŸåšã®ç§åŠçç¥èŠã§ã¯ãã®åœ±é¿ãå¿é ãããŸããéºäŒåã®å¶åŸ¡ãå€åããã²ãã ã«çµã¿èŸŒãŸããå±éºæ§ãããã®ã§ãã
ããã¬ãŒã¿ãŒã3.ã圌ããèšãããšã¯ããã¯ã¯ãã³ã¯çèã«æ®ããŸããââãããéããŸãã
ãã¢ããŠã³ãµãŒããã¯ã¯ãã³ãã¯çèå ã«çãŸãããšãæå³ãããã®ã§ã¯ãªããè¡æµããªã³ãç¯ãããã«ã¯æ¯ä¹³ã«ãŸã§å ¥ããã®ã§ããã
åŸæ¥ã®ã¯ã¯ãã³ã®ç²åãšã¯ç°ãªããmodRNAãå«ãè質ããç²åã¯è¡æµã«çãŸããŸããã代ããã«ãå¿èãè³ãèèãè èãèºãèŸèãèãåµå·£ãçŸäžžãªã©ã®éèŠãªèåšãå«ããäœå ã®ãããã现èã«æµžéããããšãã§ããŸãã
è質ããç²åã¯éåžžã«ççãèµ·ããããããæ¯æ§ããããŸãããã®ãããç¹°ãè¿ã泚å°ããããšçްèãžã®ãã¡ãŒãžãå¢å€§ããæ©æã®çŽ°èæ»ã«ã€ãªããããšãããããŸãã
é »ç¹ã«èµ·ããé節ãªå¯äœçšã¯ãå¿ççãšå¿èçã€ãŸãå¿èã®ççã§ãç¹ã«è¥ã人ã«å€ãèŠãããŸãããã®ççã¯ãæ³šå ¥ãããç²åãåã蟌ãã§ã¹ãã€ã¯ã¿ã³ãã¯è³ªãçºçŸããå¿èã®çްèã«å¯Ÿããèªå·±å ç«æ»æã®çµæã§ãããšèããããŸãã
ããã¬ãŒã¿ãŒã5. 圌ããèšãããšã¯ããmRNAã¯DNAã«çµã¿èŸŒãŸããŸãããââãããéããŸãã
ãã¢ããŠã³ãµãŒãã¯ã¯ãã³ãã®modRNAã¯DNAã«çµã¿èŸŒãŸããå¯èœæ§ãããããã®æçé åãæ£è ã®è¡æ¶²çްèããèŠã€ãããŸãã
BioNTech/Pfizer瀟ã®modRNA泚å°å€ããæ€åºãããDNAæ±æç©è³ªã¯ãã·ãã¢ã³ãŠã€ã«ã¹40ïŒSV40ïŒããã¢ãŒã¿ãŒé åãããªããµã«ãŠã€ã«ã¹é åãå«ãŸããŠããããã®é åã¯DNAã®çŽ°èæ žãžã®èŒžéãä¿é²ããããšãç¥ãããŠããŸãã
ãã®ããããã®å€æ¥DNAãç§ãã¡ã®çްèã®ã²ãã ã«çµã¿èŸŒãŸããäºæž¬ã§ããªãçµæãããããå±éºæ§ãé«ãŸããŸãã
å粟ã«é¢äžããç·æ§ãŸãã¯å¥³æ§ã®çæ®çްèã§ãã®ãããªçŸè±¡ãèµ·ããã°ãåå«ã®ã²ãã ãå€åããŸãã
ãã¯ã¯ãã³ãç±æ¥ã®é åãã²ãã ã«çµã¿èŸŒããšã倿¥éºäŒåãçºçŸããããéºäŒåå¶åŸ¡ãç°åžžã«ãªãå¯èœæ§ãé«ããåŸè ã¯ãçéºäŒåã®æŽ»æ§åãçæå¶éºäŒåã®äžæŽ»æ§åãããããå¯èœæ§ããããã©ã¡ããçãä¿é²ããŸãããã®ãªã¹ã¯ã¯ãå€ãã® ãã¯ã¯ãã³ãæ¥çš®è ã«èŠãããå ç«æå¶ã«ãã£ãŠããã«é«ãŸããè «ç现èã«å¯Ÿããå ç«åå¿ãäžååã§ããããšãæå³ããŸãããã®çµæããã¿ãŒãçãã«ãªãå¯èœæ§ãããã®ã§ãã
çããããã®ãªãŒãã¬ããã®ããŒã¹ãšãªã£ãŠããmRNAã¯ã¯ãã³æè¡ã«é¢ããç§åŠçç ç©¶çµæã¯ãäžçäžã§å ¥æå¯èœã§ãããã€ã³ã¿ãŒãããã§ã¢ã¯ã»ã¹ã§ããŸãã
ããããèªå¯åœå±ãäž»èŠã¡ãã£ã¢ã¯ã培åºçãªåè©äŸ¡ãåãäžããããšã¯ããŸããã
ã§ãããããã®mRNAã¯ã¯ãã³æè¡ã«é¢ããèŠåããããªãã®èº«ã®åãã®äººã ãšå ±æããã§ããéãåºããŠãã ããã